PLX
AMEXProtalix BioTherapeutics Inc. (DE)
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Price$2.62-0.04 (-1.69%)
02:00 PM07:45 PM
News · 26 weeks23-100%
2026-04-192026-10-11
Mix1590d
- Insider9(60%)
- SEC Filings3(20%)
- Earnings2(13%)
- Other1(7%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Schwartz Aharon4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
- PRProtalix BioTherapeutics to Participate in Upcoming September 2026 Investor ConferencesCARMIEL, Israel, Sept. 8, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that Gilad Mamlok, Senior Vice President and Chief Financial Officer, is scheduled to participate in the following two upcoming investor conferences in New York City, New York: H.C. Wainwright 28th Annual Global Investment ConferenceDate: September 14-16, 2026Company Presentation Date & Time: Monday, September 14, 2026, 2:00 p.m. EDTMorgan S
- INSIDERSEC Form 4 filed by Director Elze Christian4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
- INSIDERSEC Form 4 filed by PRESIDENT AND CEO Bashan Dror4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
- INSIDERSEC Form 4 filed by Sr. VP & COO Naos Yaron4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
- INSIDERSEC Form 4 filed by Director Ben Zvi Shmuel4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
- INSIDERSEC Form 4 filed by Director Boudes Pol F4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
- INSIDERSEC Form 4 filed by Director Melincoff Gwen A4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
- INSIDERSEC Form 4 filed by Director Forster Eliot4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
- INSIDERSEC Form 4 filed by Director Bar-Shalev Amos4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
- SECSEC Form S-8 filed by Protalix BioTherapeutics Inc. (DE)S-8 - Protalix BioTherapeutics, Inc. (0001006281) (Filer)
- SECSEC Form 10-Q filed by Protalix BioTherapeutics Inc. (DE)10-Q - Protalix BioTherapeutics, Inc. (0001006281) (Filer)
- SECProtalix BioTherapeutics Inc. (DE) filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Protalix BioTherapeutics, Inc. (0001006281) (Filer)
- PRProtalix BioTherapeutics Reports Second Quarter 2026 Financial and Business ResultsCompany to host conference call and webcast today at 8:00 a.m. EDTRevenues from selling goods increased to $19.8 million in the second quarter of 2026, up $4.4 million from the second quarter of 2025, driven primarily by sales of Elfabrio®Total revenue climbed to $53.6 million, year to date, from $25.8 million for the same period in 2025, which includes the previously reported $25.0 million Chiesi milestone paymentYear-to-date, the Company achieved profitability with a net income of $22.1 millionThe Company reiterates full-year 2026 guidance of $78.0 million to $83.0 million in total revenuePRX-115 Phase 2 study continues to advance as planned, with top-line results anticipated in the second
- PRProtalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026Company to host conference call and webcast at 8:00 a.m. EDTCARMIEL, Israel, Aug. 5, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the quarter ended June 30, 2026 and provide a business update on August 12, 2026. Management will host a conference call to discuss the financial results and provide an update on recent corporate and regulatory developments.Conference Ca
- SECProtalix BioTherapeutics Inc. (DE) filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Protalix BioTherapeutics, Inc. (0001006281) (Filer)
- SECProtalix BioTherapeutics Inc. (DE) filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Protalix BioTherapeutics, Inc. (0001006281) (Filer)
- SECSEC Form 10-Q filed by Protalix BioTherapeutics Inc. (DE)10-Q - Protalix BioTherapeutics, Inc. (0001006281) (Filer)
- SECProtalix BioTherapeutics Inc. (DE) filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Protalix BioTherapeutics, Inc. (0001006281) (Filer)
- PRProtalix BioTherapeutics Reports First Quarter 2026 Financial and Business ResultsCompany to host conference call and webcast today at 8:00 a.m. EDTElfabrio commercial execution continues following European Commission approval of the 2 mg/kg every–4–weeks (E4W) dosing regimen; $25 million milestone received from ChiesiPRX–115 Phase 2 study continues to advance as planned with top–line results anticipated in the second half of 2027The Company reaffirms its previously stated 2026 revenue guidance of $78.0 – $83.0 million including the $25.0 million milestone received from ChiesiCash, cash equivalents, and short–term bank deposits were $51 million as of March 31, 2026, providing sufficient capital to fund ongoing operations including the Phase 2 RELEASE clinical trial of PRX
- PRProtalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026Company to host conference call and webcast at 8:00 a.m. EDTCARMIEL, Israel, May 6, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the quarter ended March 31, 2026 and provide a business update on May 13, 2026. Management will host a conference call to discuss the financial results and provide an update on recent corporate and regulatory developments.Conference Call Details:Date: Wednesday, May 13, 2026Ti
- SECSEC Form DEF 14A filed by Protalix BioTherapeutics Inc. (DE)DEF 14A - Protalix BioTherapeutics, Inc. (0001006281) (Filer)
- INSIDERAmendment: New insider Mamlok Gilad claimed ownership of 3,631 shares (SEC Form 3)3/A - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
- SECSEC Form 10-K filed by Protalix BioTherapeutics Inc. (DE)10-K - Protalix BioTherapeutics, Inc. (0001006281) (Filer)
- SECProtalix BioTherapeutics Inc. (DE) filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Protalix BioTherapeutics, Inc. (0001006281) (Filer)
PLX FAQ
5 questionsWhat does Protalix BioTherapeutics Inc. (DE) do?
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed...Where does PLX stock trade?
Protalix BioTherapeutics Inc. (DE) (PLX) is listed on AMEX.What sector and industry is PLX in?
Protalix BioTherapeutics Inc. (DE) operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What companies are similar to PLX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare PLX side-by-side with any of them on Quantisnow.How can I track PLX on Quantisnow?
Quantisnow aggregates Protalix BioTherapeutics Inc. (DE)'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PLX to receive live email and push alerts on every new disclosure.